Wrocław, 06/08/2022

Current Report No 12/2022

Market authorisation for sales of Genomtec® ID.

The Management Board of Genomtec S.A. („Company", „Issuer") registered in Wroclaw, Poland, hereby informs that after expiry of the legislative deadline prerequisite when registering a new medical device for in-vitro diagnostic use at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Genomtec® ID Respiratory Panel 5 – Plex has been granted full market authorisation for sales in the European Union.

Genomtec® ID Respiratory Panel 5 - Plex is an automated, genetic in-vitro diagnostic test utilizing a microfluidic reaction card along with the patented isothermal nucleic acid amplification method SNAAT® combined with proprietary assays integrated on the card to detect SARS-CoV-2 virus, respiratory syncytial viruses types A and B, Influenza viruses A and B, Chlamydophila pneumoniae and Mycoplasma pneumoniae bacteria that cause respiratory infections.

Market authorisation of the Company's flagship product is an important milestone in the development of Genomtec S.A. and will have a significant impact on the Issuer's operations and revenues. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.